RAD receives approval for Phase 1 therapeutic study of NSCLC
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Appendix 4E and FY23 Financial Report
- TerThera Terbium-161 isotope supply agreement expanded
- FDA Pre-IND meeting supports an IND application for RAD 101
- RAD 301 receives FDA Orphan Drug Designation
- Agreement with TerThera to supply Terbium-161 isotope
Later from Radiopharm Theranostics
- FDA green light for diagnostic Phase 1 pancreatic trial
- Entitlement Offer to raise approximately $10 million
- Entitlement Offer Documents
- Radiopharm receives $4.85M R&D tax incentive
- Completion of Entitlement Offer
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics